Literature DB >> 9165106

Escape mutants of HIV-1 proteinase: enzymic efficiency and susceptibility to inhibition.

S I Wilson1, L H Phylip, J S Mills, S V Gulnik, J W Erickson, B M Dunn, J Kay.   

Abstract

Genes encoding a number of mutants of HIV-1 proteinase were sub-cloned and expressed in E. coli. The proteinases containing mutations of single residues (e.g., G48V, V82F, I84V and L90M) were purified and their catalytic efficiencies relative to that of wild-type proteinase were examined using a polyprotein (recombinant HIV-1 gag) substrate and several series of synthetic peptides based on the -Hydrophobic * Hydrophobic-, -Aromatic * Pro- and pseudo-symmetrical types of cleavage junction. The L90M proteinase showed only small changes, whereas the activity of the other mutant enzymes was compromised more severely, particularly towards substrates of the -Aromatic * Pro- and pseudo-symmetrical types. The susceptibility of the mutants and the wild-type proteinase to inhibition by eleven different compounds was compared. The L90M proteinase again showed only marginal changes in its susceptibility to all except one of the inhibitors examined. The K(i) values determined for one inhibitor (Ro31-8959) showed that its potency towards the V82F, L90M, I84V and G48V mutant proteinases respectively was 2-, 3-, 17- and 27-fold less than against the wild-type proteinase. Several of the other inhibitors examined form a systematic series with Ro31-8959. The inhibition constants derived with these and a number of other inhibitors, including ABT-538 and L-735,524, are used in conjunction with the data on enzymic efficiency to assess whether each mutation in the proteinase confers an advantage for viral replication in the presence of any given inhibitor.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9165106     DOI: 10.1016/s0167-4838(96)00224-5

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  12 in total

1.  Real-time measurements of dark substrate catalysis.

Authors:  D Xie; L Suvorov; J W Erickson; A S Gulnik
Journal:  Protein Sci       Date:  1999-11       Impact factor: 6.725

2.  Lack of synergy for inhibitors targeting a multi-drug-resistant HIV-1 protease.

Authors:  Nancy M King; Laurence Melnick; Moses Prabu-Jeyabalan; Ellen A Nalivaika; Shiow-Shong Yang; Yun Gao; Xiaoyi Nie; Charles Zepp; Donald L Heefner; Celia A Schiffer
Journal:  Protein Sci       Date:  2002-02       Impact factor: 6.725

3.  Pulsed EPR characterization of HIV-1 protease conformational sampling and inhibitor-induced population shifts.

Authors:  Zhanglong Liu; Thomas M Casey; Mandy E Blackburn; Xi Huang; Linh Pham; Ian Mitchelle S de Vera; Jeffrey D Carter; Jamie L Kear-Scott; Angelo M Veloro; Luis Galiano; Gail E Fanucci
Journal:  Phys Chem Chem Phys       Date:  2016-02-17       Impact factor: 3.676

4.  Validating the vitality strategy for fighting drug resistance.

Authors:  Nidhi Singh; Maria P Frushicheva; Arieh Warshel
Journal:  Proteins       Date:  2012-01-31

5.  The role of select subtype polymorphisms on HIV-1 protease conformational sampling and dynamics.

Authors:  Xi Huang; Manuel D Britto; Jamie L Kear-Scott; Christopher D Boone; James R Rocca; Carlos Simmerling; Robert Mckenna; Michael Bieri; Paul R Gooley; Ben M Dunn; Gail E Fanucci
Journal:  J Biol Chem       Date:  2014-04-17       Impact factor: 5.157

6.  Analysis of the S3 and S3' subsite specificities of feline immunodeficiency virus (FIV) protease: development of a broad-based protease inhibitor efficacious against FIV, SIV, and HIV in vitro and ex vivo.

Authors:  T Lee; G S Laco; B E Torbett; H S Fox; D L Lerner; J H Elder; C H Wong
Journal:  Proc Natl Acad Sci U S A       Date:  1998-02-03       Impact factor: 11.205

7.  Computational mutation scanning and drug resistance mechanisms of HIV-1 protease inhibitors.

Authors:  Ge-Fei Hao; Guang-Fu Yang; Chang-Guo Zhan
Journal:  J Phys Chem B       Date:  2010-07-29       Impact factor: 2.991

8.  Effects of Hinge-region Natural Polymorphisms on Human Immunodeficiency Virus-Type 1 Protease Structure, Dynamics, and Drug Pressure Evolution.

Authors:  Zhanglong Liu; Xi Huang; Lingna Hu; Linh Pham; Katye M Poole; Yan Tang; Brian P Mahon; Wenxing Tang; Kunhua Li; Nathan E Goldfarb; Ben M Dunn; Robert McKenna; Gail E Fanucci
Journal:  J Biol Chem       Date:  2016-08-30       Impact factor: 5.157

9.  Toward a universal inhibitor of retroviral proteases: comparative analysis of the interactions of LP-130 complexed with proteases from HIV-1, FIV, and EIAV.

Authors:  J Kervinen; J Lubkowski; A Zdanov; D Bhatt; B M Dunn; K Y Hui; D J Powell; J Kay; A Wlodawer; A Gustchina
Journal:  Protein Sci       Date:  1998-11       Impact factor: 6.725

10.  Elucidating a relationship between conformational sampling and drug resistance in HIV-1 protease.

Authors:  Ian Mitchelle S de Vera; Adam N Smith; Maria Cristina A Dancel; Xi Huang; Ben M Dunn; Gail E Fanucci
Journal:  Biochemistry       Date:  2013-05-01       Impact factor: 3.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.